Substrate use switches from fatty acids toward glucose in pressure overload-induced cardiac hypertrophy with an acceleration of glycolysis being characteristic. The activation of AMP-activated protein kinase (AMPK) observed in hypertrophied hearts provides one potential mechanism for the acceleration of glycolysis. Here, we directly tested the hypothesis that AMPK causes the acceleration of glycolysis in hypertrophied heart muscle cells. The H9c2 cell line, derived from the embryonic rat heart, was treated with arginine vasopressin (AVP; 1 M) to induce a cellular model of hypertrophy. Rates of glycolysis and oxidation of glucose and palmitate were measured in nonhypertrophied and hypertrophied H9c2 cells, and the effects of inhibition of AMPK were determined. AMPK activity was inhibited by 6-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrrazolo-[1,5-a]pyrimidine (compound C) or by adenovirus-mediated transfer of dominant negative AMPK. Compared with nonhypertrophied cells, glycolysis was accelerated and palmitate oxidation was reduced with no significant alteration in glucose oxidation in hypertrophied cells, a metabolic profile similar to that of intact hypertrophied hearts. Inhibition of AMPK resulted in the partial reduction of glycolysis in AVP-treated hypertrophied H9c2 cells. Acute exposure of H9c2 cells to AVP also activated AMPK and accelerated glycolysis. These elevated rates of glycolysis were not altered by AMPK inhibition but were blocked by agents that interfere with Ca 2ϩ signaling, including extracellular EGTA, dantrolene, and 2-aminoethoxydiphenyl borate. We conclude that the acceleration of glycolysis in AVP-treated hypertrophied heart muscle cells is partially dependent on AMPK, whereas the acute glycolytic effects of AVP are AMPK independent and at least partially Ca 2ϩ dependent. cardiac hypertrophy; energy metabolism; glucose utilization
cellular high-energy phosphates, including ATP and phosphocreatine (3, 14) . Additionally, it has been shown that AMPK can be activated by hormones acting through G q -linked G protein-coupled receptors and a Ca 2ϩ -dependent pathway independent of any changes in the energy status of the cells (14, 26) . Once activated, AMPK mediates the inhibition of energyconsuming pathways and stimulation of energy-producing pathways, such as fatty acid oxidation, glucose uptake, and glycolysis (3, 14) .
The activation of AMPK stimulates fatty acid oxidation in muscle by increasing the uptake of fatty acids across cellular and mitochondrial membranes (3, 14, 33) . Key actions of AMPK include the translocation of fatty acid transport proteins to the sarcolemma, increased recruitment of lipoprotein lipase to the capillary endothelium (2, 10, 14) , and lowering of the concentration of malonyl-CoA, a key allosteric inhibitor of carnitine palmitoyltransferase-I (14, 37) . Malonyl-CoA levels are reduced through the phosphorylation and inactivation of acetyl-CoA carboxylase, which synthesizes malonyl-CoA, and, possibly, through the phosphorylation and activation of malonylCoA decarboxylase (14, 55) . The effects of AMPK on glucose metabolism in the heart are accounted for by the enhanced translocation of glucose transport proteins to the sarcolemma (14, 43) and by the stimulation of glycolysis through the phosphorylation and activation of 6-phosphofructo-2-kinase (PFK-2) (36) . The consequent increase in fructose-2,6-diphosphate (F-2,6-P 2 ) leads to the allosteric activation of PFK-1, a major determinant of glycolytic rates in the heart and other tissues (36, 53) .
Oxidation of long-chain fatty acids, the major source of energy in the myocardium, is low in hypertrophied hearts studied as isolated preparations or in vivo (1, 45) , and it has been argued that this is explained by the reduced expression of oxidative enzymes and fatty acid uptake/transport proteins as well as low levels of myocardial carnitine (4, 44, 46) . As a result, energy production in hypertrophied hearts is more dependent on carbohydrates with an acceleration of glycolysis being characteristic (1, 40, 45, 52) .
Activation of AMPK in hypertrophied hearts has been observed in a number of studies (1, 40, 52) . Furthermore, we (1) have recently shown that accelerated rates of glycolysis are normalized when fatty acid oxidation is elevated to rates similar to those in nonhypertrophied hearts. At the same time, elevated activity of AMPK in hypertrophied hearts is correspondingly reduced to values observed in nonhypertrophied hearts. Although these data provide correlative support for the view that AMPK is responsible for the acceleration of glycolysis in hypertrophied hearts, other mechanisms remain possible.
The present investigation was designed to directly test the hypothesis that AMPK is responsible for the acceleration of glycolysis in hypertrophied heart muscle cells. Cultured H9c2 cells, a cell line derived from the embryonic rat heart (21), were used as an in vitro model of cardiac myocyte hypertrophy in which AMPK activity was selectively altered by pharmacological and molecular approaches. H9c2 cells were hypertrophied by exposure to arginine vasopressin (AVP), which is a peptide neurohormone that is significantly and chronically elevated in the plasma of heart failure patients (18, 32) and experimental animals (15) and has effects on processes that participate in the pathogenesis of heart failure, including body fluid regulation, vascular tone, and cardiac contractile function and remodeling (32) . AVP may contribute to structural remodeling in heart failure (18) as it has been shown to cause hypertrophy of heart muscle cells in culture (8, 39) and stimulate protein synthesis in isolated hearts (16) . Moreover, Hupf and colleagues (23) have demonstrated that the heart possesses a local AVP system that is activated in response to pressure overload, suggesting that, in pathological settings, the heart may not only respond to circulating AVP but also to locally produced AVP in a paracrine or autocrine fashion.
MATERIALS AND METHODS

Culture and treatment of H9c2 cells. H9c2 (2-1) cells (passage 12,
American Type Culture Collection, Manassas, VA) were cultured in DMEM containing 10% FBS and 100 U/ml penicillin-streptomycin at 37°C in a humified atmosphere of 95% O 2-5% CO2 (8) . Differentiation toward a cardiac phenotype was induced by culture in DMEM containing 1% horse serum and 0.1 M all-trans-retinoic acid for 4 days (8, 38) , with the medium being changed daily. Retinoic acid was prepared in the dark in DMSO and stored at Ϫ20°C until use, and the concentration of DMSO in the culture media was Ͻ0.2%.
Hypertrophy of H9c2 cells was induced by exposure of differentiated H9c2 cells to DMEM-F-12 media containing 0.5% horse serum with or without 1 M AVP for 48 h, as previously described (8) . After 48 h, AVP-containing media were replaced with Krebs-Henseleit (KH) solution containing 0.4 mM palmitate prebound to 3% BSA, 5.5 mM glucose, and 10 Ϫ7 M insulin. Cells were studied over 8 h under these conditions with tracer amounts of labeled [5- 3 H]glucose (1.0 Ci/ml), [U-
14 C]glucose (1.0 Ci/ml), or [U-14 C]palmitate (0.4 Ci/ ml) added during the last hour of study to measure glycolysis, glucose oxidation, and fatty acid oxidation, respectively, in separate experiments. A delay of 7-8 h before measurements of substrate use was chosen to minimize residual direct effects of AVP.
Another set of experiments was performed to investigate the acute metabolic actions of AVP on H9c2 cells. Rates of glycolysis were measured in experiments conducted over 2 h in KH solution containing 0.4 mM palmitate prebound to 3% fatty acid-free BSA, 5.5 mM [5- 3 H]glucose (1.0 Ci/ml), and 10 Ϫ7 M insulin with or without AVP. Slightly different conditions were used in selected experiments as shown in the figures. The lowest concentration of AVP capable of stimulating glycolysis was assessed by exposing H9c2 cells to a range of AVP concentrations, including concentrations observed in the setting of heart failure in humans and in rodents (7, 9, 15) .
Assessment of cellular hypertrophy. Cellular hypertrophy was evaluated by measuring changes in protein synthesis and content as well as DNA synthesis and the expression of atrial natriuretic factor (ANF), a well-recognized marker of pathological cardiac hypertrophy (13, 35) . Protein synthesis induced by AVP treatment was quantitated by measuring the incorporation of phenylalanine into cells exposed to [ 14 C]phenylalanine (1.0 Ci/ml), as previously described (47) . [ 14 C]phenylalanine was present in culture media during the first 24 h in either the presence or absence of AVP. DNA synthesis was determined by measuring the incorporation of [ 14 C]thymidine (1.0 Ci/ml) into cells during the first 24 h in either the absence or presence of AVP, as previously described (8) . Experiments were terminated by removing media, washing with ice-cold phosphate buffer, and adding ice-cold 10% trichloroacetic acid to precipitate proteins. After an overnight incubation at 4°C, precipitates were dissolved in 1 M NaOH-0.01% SDS for 2 h at 37°C. Aliquots of the resulting solution were counted in a liquid scintillation counter or used to determine protein content. Protein content of the cultures was determined using a commercial bicinchoninic acid protein assay kit (procedure no. TPRO-562, Sigma Chemical, St. Louis, MO).
ANF expression was measured in H9c2 cell lysate using a commercially available ELISA kit (R&D Systems, Mississauga, ON, Canada). Lysis of cells was performed using homogenizaion buffer (pH 7.5) containing MOPS (20 mM), sucrose (250 mM), KCl (150 mM), EDTA (1 mM), benzamidine (2.5 mM), pepstatin A (3 M), leupeptin (5 M), glutathione (2.5 mM), PMSF (0.5 mM), and microcystin-LR (0.14 g/ml). The cell suspension was sonicated and then centrifuged for 10 min at 13,000 g at 4°C. The supernatant, which contained 10 g total protein, was then used to measure ANF expression.
Measurement of substrate utilization. Oxidation of palmitate and glucose was measured using modifications of previously described methods (22, 45) . Briefly, preoxygenated KH solution containing [U- 14 C]palmitate (0.4 Ci/mol) complexed to BSA or [U- 14 C]glucose (1.0 Ci/ml) was added to cells in a final volume of 2 ml. The flasks were then sealed with a rubber stopper fitted with a scintillation vial containing cellulose filter paper soaked with 0.3 ml of 1 M hyamine hydroxide. Rates of fatty acid and glucose oxidation were measured by quantitative collection of 14 CO2 released as a gas and dissolved in the cell media as [
14 C]bicarbonate, respectively. After an incubation for 1 h at 37°C, the reaction was stopped by the injection of 5 M H2SO4 (0.5 ml), which also liberates 14 CO2 dissolved in the KH solution. The filter papers were taken for scintillation counting after 2 h of gentle shaking at room temperature. Glycolysis was determined by measuring the rate of production of 3 H2O from trace amounts of [5Ј-
3 H]glucose (1.0 Ci/ml) added to the media (45 Expression of metabolic proteins. Expression of key proteins involved in control of glucose catabolism, including glucose transporter (GLUT)-4, hexokinase (HK)-2, the E1␣-subunit of the pyruvate dehydrognase complex (PDC-E1␣), GLUT-1, phosphorylation of PFK-2 at Ser 466 , and the ␣-catalytic subunit of AMPK (␣-pan AMPK), was determined in control and hypertrophied H9c2 cells by immunoblot analysis, as previously described (1, 45) . Briefly, 30 g of H9c2 cell lysate were separated by electrophoresis on 5-12.5% SDS-polyacrylamide gels and transferred by electroblotting to a nitrocellulose membrane. Membranes were probed with antibodies against GLUT-4 (1:1,000 dilution, Cell Signaling Technology, Missisauga, ON, Canada), GLUT-1 (10 g/ml, Santa Cruz Biotechnology, Santa Cruz, CA), HK-2 (1:500 dilution, Santa Cruz Biotechnology), p-PFK-2 (1:200 dilution, Santa Cruz Biotechnology), PDC-E1␣ (1:100,000 dilution, Santa Cruz Biotechnology), and ␣-pan AMPK (1:1,000 dilution, Upstate Biotechnologies, Lake Placid, NY). After an incubation with the appropriate secondary antibody, the signal was detected by ECL, and band intensities for each individual protein were quantified by densitometry, corrected for background staining, and normalized to the signal for GAPDH (1:15,000 dilution, Molecular Probes, Eugene, OR) or total PFK-2 (1:200 dilution, Santa Cruz Biotechnology).
AMPK activity and its inhibition. Total AMPK activity was measured in H9c2 cell homogenates after immunopreciptation or precipitation with saturated ammonium sulfate by determining the incorporation of 32 P into the synthetic AMARA peptide, AMARAASAAALARRR, as previously described (1) . The extent of phosphorylation of AMPK was also determined by immunoblot analysis using a previously described method (1) .
To suppress AMPK pharmacologically after the induction of hypertrophy by AVP, H9c2 cells were exposed to 40 M of 6-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrrazolo-[1,5-a]pyrimidine (compound C; EMD Chemicals, San Diego CA) (59) for 8 h in KH solution containing 0.4 mM palmitate prebound to 3% BSA, 5.5 mM glucose, and 10 Ϫ7 M insulin. As an alternative to pharmacological inhibition by compound C, experiments were carried out with a dominant negative (DN) form of AMPK (Ad-DN-AMPK). Recombinant, replication-deficient adenovirus containing mutant DN AMPK was constructed as previously described (25) . Briefly, cDNA containing a DN catalytic ␣ 2-subunit carrying the D157A mutation (48, 56) was subcloned into a pAdTrack shuttle vector, linearized with PmeI, and inserted into adenovirus using the pAdEasy-1 system for homologous recombination in Esherichia coli. The recombinant adenovirus vector also contains the gene for green fluorescent protein (Ad-GFP) to serve as a reporter of the extent of viral infection and protein expression.
For these experiments, H9c2 cells were infected with adenovirus containing Ad-GFP [multiplicity of infection (MOI): 150] or Ad-DN-AMPK plus GFP (MOI: 150) by incubation in DMEM media containing 1% horse serum for 24 h after the removal of AVP. Media were replaced with KH solution containing 0.4 mM palmitate prebound to 3% BSA, 5.5 mM glucose, and 10 Ϫ7 M insulin, and rates of glycolysis were measured by the addition of tracer amounts of [5- 3 H]glucose 7 h later, as described above. Similarly, the potential role of AMPK in the acute metabolic actions of AVP was assessed using pharmacological and molecular means to inhibit AMPK in H9c2 cells. Specifically, H9c2 cells were exposed to 40 M compound C for 30 min before the switch to KH solution containing fatty acid, glucose, and insulin with or without 1 M AVP. When used, compound C was present for the entire study period. H9c2 cells exposed to vehicle served as controls for these experiments. For inhibition by Ad-DN-AMPK, cells were exposed to Ad-GFP or Ad-DN-AMPK plus GFP for 24 h before an acute exposure to AVP.
Determination of the role of Ca 2ϩ in the acute metabolic actions of AVP. Binding of AVP to the V1a receptor, the receptor subtype shown to be involved with the hypertrophic response to AVP (16) , leads to the activation of phospholipase C, production of inositol 1,4,5-trisphosphate (IP 3) and diacylglycerol (DAG), mobilization of intracellular Ca 2ϩ , and influx of extracellular Ca 2ϩ (8, 51) . By selectively modulating intracellular Ca 2ϩ mobilization and extracellular Ca 2ϩ influx, we evaluated the role of Ca 2ϩ in mediating the metabolic response of H9c2 cells to AVP. In one series of experiments, H9c2 cells were pretreated for 30 min with 25 M dantrolene, an inhibitor of Ca 2ϩ release from the sarcoplasmic reticulum (SR) via the ryanodine receptor (57) . To evaluate the involvement of the IP 3 receptor, whose activation also leads to Ca 2ϩ release from the SR, cells were pretreated for 5 min with 100 M 2-aminoethoxydiphenyl borate (2-APB), a noncompetitive IP 3 receptor antagonist (34 (Fig. 1B) , [ 14 C]phenylalanine incorporation (Fig. 1C) , and ANF expression (Fig. 1D) , indicating that H9c2 cells exposed chronically to AVP exhibit several major characteristics of hypertrophy. Furthermore, rates of glycolysis were accelerated by ϳ80% in H9c2 cells after AVP treatment for 48 h (Fig. 2A ). There were no significant differences in glucose oxidation between hypertrophied H9c2 cells and nonhypertrophied cells (Fig. 2B) . However, rates of fatty acid oxidation were significantly decreased in hypertrophied H9c2 cells compared with nonhypertrophied cells (Fig. 2C) . Notably, when H9c2 cells were treated with AVP for 48 h and AVP was then removed, the accelerated rates of glycolysis persisted for at least a further 48 h after AVP removal (data not shown). Accompanying the changes in substrate use, expression of several key proteins involved in the control of glucose metabolism was altered in hypertrophied H9c2 cells (Fig. 3) . Specifically, the expression of HK-2 was significantly increased, whereas those of GLUT-4 and PDC-E1␣ were slightly but significantly decreased (Fig. 3 ). There were no significant changes in GLUT-1 expression (Fig. 3) . In hypertrophied H9c2 cells, phosphorylation of PFK-2 was in- creased at Ser 466 , a site that is responsible for the activation of PFK-2 in heart muscle (5 , n ϭ 31-32 per group, P Ͻ 0.05), whereas the expression of the catalytic subunits of AMPK did not differ significantly between the two groups (data not shown).
To determine if AMPK is responsible for the accelerated rates of glycolysis observed in H9c2 cells hypertrophied by AVP, two approaches were used to suppress AMPK activity. In one approach, AMPK was inhibited by the expression of Ad-DN-AMPK, and in the alternate pharmacological approach, AMPK was inhibited by incubating cells with compound C. Exposure of H9c2 cells to Ad-DN-AMPK (MOI: 150) for 24 h resulted in nearly 100% gene transfer as demonstrated by the expression of GFP (Fig. 4A) . AMPK activity was reduced in control and hypertrophied H9c2 cells infected with Ad-DN-AMPK (Fig. 4B) . Data from cells exposed to Ad-GFP were comparable with corresponding control and hypertrophied cells (data not shown). The effectiveness of inhibition of AMPK was confirmed by the substantial abrogation of the acceleration of glycolysis caused by mannitol and oligomycyin, two potent activators of AMPK (Table 1) (19, 24) . Likewise, compound C treatment resulted in a substantial reduction in AMPK activity in hypertrophied and nonhypertrophied H9c2 cells (Fig. 4C) , a reduction that was greater than that caused by Ad-DN-AMPK.
It should be noted that the extent of hypertrophy, as assessed by total protein content, was comparable in the presence (21.8 Ϯ 1.8% of control values, n ϭ 4) or absence of Ad-DN-AMPK (24.2 Ϯ 3.0% of control values, n ϭ 5, P ϭ NS), indicating that exposure of cells to DN-AMPK in did not lead to the stimulation or regression of hypertrophy. Inhibition of AMPK after induction of hypertophy in H9c2 cells by AVP had only a partial effect on rates of glycolysis ( Fig. 5 and Table 2 ). This effect was most evident when the variability of glycolytic rates caused by the inhibitors themselves was accounted for (Table 2 ). Interestingly, suppression of glycolytic rates was relatively greater for compound C than for Ad-DN-AMPK, a finding that likely reflects the greater reduction in AMPK activity caused by compound C (Fig. 4C) . Glycolytic rates in Ad-GFP-treated cells were comparable with those in the corresponding control and hypertrophied H9c2 cells (data not shown). (Fig. 6A) . The lowest effective dose of AVP, 10 nM, was comparable to concentrations of circulating AVP seen in the setting of heart failure (7, 9) . To determine the receptor involved in AVP-induced stimulation of glycolysis, H9c2 cells were pretreated with either d(CH 2 ) 5 (30) . Cells were exposed to these receptor antagonists for 30 min before the addition of 1 M AVP. The V 1a receptor antagonist completely abolished the acceleration of glycolysis (Fig. 6B) , whereas the V 2 receptor antagonist had no effect.
AVP acutely accelerates glycolysis in H9c2 cells. Treatment of H9c2 cells with AVP for as little as 2 h led to a dosedependent stimulation of glycolysis
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, and acute stimulation of glycolysis by AVP. Acute exposure of H9c2 cells to AVP resulted in a significant twofold increase in the measured activity of AMPK (Fig. 7A ) that was significantly and markedly reduced by both Ad-DN-AMPK and compound C (Fig. 7A) . However, inhibition of AMPK by either Ad-DN-AMPK or compound C did not cause a significant reduction in glycolysis in H9c2 cells treated for this short duration with AVP (Fig. 7 , B and C) even when inhibitor effects were taken into account (Table 2) ; this is a result differing from that seen in H9c2 cells hypertrophied by longer-term (48 h) exposure to AVP (Fig. 5 and Table 2 ). Given the well-known effects of AVP on cellular Ca 2ϩ (41, 50) and the potential for Ca 2ϩ to accelerate glucose use (28, 58) , pharmacological agents that interfere with Ca 2ϩ entry or intracellular release from Ca 2ϩ stores were used to assess the role of Ca 2ϩ in the acute metabolic actions of AVP. In contrast to AMPK inhibition, treatment of H9c2 cells with 2-APB completely abolished the effect of AVP on glycolysis (Fig. 8A ), whereas incubation with dantrolene (Fig. 8B) or EGTA (Fig. 8C) partially attenuated the elevation in glycolysis caused by AVP. These data indicate that the acute stimulation of glycolysis by AVP is mediated by changes in cellular Ca 2ϩ , especially Ca 2ϩ release from the SR by stimulation of the 2-APB receptor.
DISCUSSION
In the present study, we demonstrate that AVP induces cellular hypertrophy in H9c2 cells with parallel metabolic remodeling of heart muscle cells characterized by an acceler- ); n ϭ 3-14 per group. Ad-DN-AMPK, adenovirus-mediated transfer of dominant negative AMP-activated protein kinase. *Significantly different from the corresponding no treatment group (P Ͻ 0.05); †significantly different from the corresponding no Ad-DN-AMPK group (P Ͻ 0.05).
ation of glycolysis and a reduction in long-chain fatty acid oxidation. The metabolic changes observed in hypertrophied heart muscle cells resemble those observed in intact hypertrophied hearts and include alterations in the expression of metabolic proteins and activation of AMPK. We demonstrate, for the first time, that the acceleration of glycolysis in hypertrophied heart muscle cells is only partially dependent on AMPK, a finding that suggests that factors in addition to AMPK are involved. Our results also indicate that the rapid acceleration of glycolysis caused by the acute administration of AVP is not dependent on AMPK activation, even though AMPK is activated. Rather, AVP acutely stimulates glycolysis by a Ca 2ϩ -dependent mechanism.
Hypertrophy, as assessed by increased protein content and synthesis as well as elevation of ANF (Fig. 1) , was produced in the heart muscle cell line H9c2 by prolonged exposure to AVP for 48 h, in keeping with results from previous studies (8, 16, 39) . AVP is released from the posterior pituitary and affects body fluid balance and vascular tone (17, 32) . Levels of AVP are significantly and chronically elevated in the plasma of patients and experimental animals with heart failure (7, 9, 15). Moreover, the heart possesses a local AVP system that is activated in response to pressure overload and may act in a paracrine or autocrine fashion (23) . Systemic and myocardial AVP may therefore contribute to structural remodeling of the failing heart.
In addition to causing hypertrophy, AVP leads to metabolic remodeling of H9c2 cells, activating glycolysis and reducing long-chain fatty acid oxidation (Fig. 2) . Those metabolic alterations in hypertrophied H9c2 cells persist for at least 2 days after the removal of AVP (data not shown), indicating that the changes are related to a chronic remodeling process. The metabolic alterations observed in hypertrophied H9c2 cells recapitulate those seen in intact hearts from experimental animal models of cardiac hypertrophy induced by pressure overload (1, 40, 45, 52) .
The changes observed here in the expression of HK-2, GLUT-4, and PDC-E1␣ (Fig. 3) are consistent with the changes in activity or expression of these proteins observed in some models of hypertrophy in the intact heart (11) and heart failure (49), but not all studies have given consistent results (31, 45) . Collectively, these findings indicate that while changes commonly occur in the expression of proteins and enzymes directly controlling glucose catabolism in hypertro- Values are means Ϯ SE (expressed as percentages of the control value); n ϭ 3-25 per group. AVP, arginine vasopressin. *Significantly different from control (P Ͻ 0.05); †significantly different from the corresponding group not exposed to AVP (P Ͻ 0.05); ‡significantly different from AVP (P Ͻ 0.05). phied heart muscle, the direction and extent of change vary between models. In addition, it was found that the phosphorylation of PFK-2 on Ser 466 was increased (Fig. 3) , indicating greater activation. AMPK is known to increase PFK-2 activity by causing the phosphorylation of Ser 466 (5) . The activation of PFK-2 leads to increased the production of F-2,6-P 2 , a potent activator of the key glycolytic enzyme PFK-1, ultimately leading to increased rates of glycolysis.
The reduction of glycolysis in hypertrophied H9c2 cells observed in the present study after the inhibition of AMPK by complementary pharmacological and molecular approaches is a direct demonstration that AMPK contributes to the acceleration of glycolysis in hypertrophied heart muscle cells. However, inhibition of AMPK failed to completely normalize rates of glycolysis (Fig. 5) , suggesting that other factor(s) also contribute to the increased glycolysis in this setting. In addition to the effects related to hypertrophic and metabolic remodeling, acute exposure of H9c2 cells to AVP (Fig. 6A ) accelerated glycolysis at concentrations of AVP comparable with those reported in the plasma of patients and rodents with congestive heart failure, which, therefore, is potentially clinically relevant $ significantly different from AVP (P Ͻ 0.05); #signifi-cantly different from Ad-DN-AMPK or compound C (P Ͻ 0.05). n ϭ 3-9 per group. (7, 9, 15) . A stimulatory effect of AVP on glucose catabolism has been previously described in a variety cell types, tissues, and organs, including isolated perfused rat hearts (12, 27, 54) . Our results clearly demonstrate that the acceleration of glycolysis in H9c2 cells is a direct effect of AVP on heart muscle cells.
AVP exerts its actions through binding to three specific receptor subtypes, including V 1a , V 2 , and V 3 receptors, all of which belong to the G q -coupled receptor family (50) . We show that AVP exerts its acute metabolic effects in H9c2 cells via the V 1a receptor (Fig. 6B) , the receptor subtype responsible for AVP-induced hypertrophy of heart muscle cells (39) . The V 1a receptor acts independently of the cAMP cascade and instead leads to the sequential activation of phospholipases, hydrolysis of membrane phosphoinositides, release of IP 3 and DAG, and mobilization of SR Ca 2ϩ stores, followed by the sustained entry of extracellular Ca 2ϩ (50) . Acute exposure to AVP causes a substantial elevation of AMPK activity (Fig. 7A ), but the acute AVP-induced acceleration of glycolysis in H9c2 cells is independent of AMPK because compound C or Ad-DN-AMPK failed to block the glycolytic response to AVP (Fig. 7, B and C) . Our data strongly implicate intracellular and extracellular Ca 2ϩ -dependent pathways (Fig. 8) in the acute AVP-induced stimulation of glycolysis in H9c2 cells, consistent with the effects of AVP in the liver (29) . It should be recognized, however, that the agents used in our study are not necessarily fully selective. For example, 2-APB may also influence other aspects of Ca 2ϩ homeostasis, such as inhibition of Ca 2ϩ -ATPase activity and the store-operated Ca 2ϩ entry channel (6) . Further studies will be required to fully define the specific Ca 2ϩ -dependent pathways involved in H9c2 cells.
The failure to observe an effect of AMPK inhibition on the acceleration of glycolysis by acute exposure to AVP was surprising and is also difficult to easily explain. Presumably, what our data indicate is that the control of glycolysis differs between acute and chronic exposure to AVP. In the acute setting, AVP-induced changes in intracellular Ca 2ϩ are the primary factors responsible with no measurable contribution from AMPK. With chronic exposure, AMPK becomes only partially responsible for the acceleration in glycolysis observed. Taken together, our findings serve to emphasize that multiple factors participate in the control of rates of glycolysis. Why significant elevations in AMPK activity caused by acute AVP exposure does not participate in this control is unknown at this time and requires further investigation.
The functional significance of alterations in glycolysis caused by acute exposure to AVP is not immediately apparent. It is possible that AVP may participate in pathological remodeling of the heart at different levels and over different time frames. For instance, AVP may participate in altering the metabolic phenotype of hearts exposed to pressure overload over a short time frame and serve as an early adaptive and transient response. Over a longer time frame, continued exposure to AVP would lead to more permanent alterations in structure and metabolism, as observed in hypertrophied and failing hearts.
In the present study, H9c2 cells were used as an in vitro model system to investigate the effect of AVP on metabolic remodeling in the heart. These cells, which were originally derived from the rat embryonic ventricle, have morphological characteristics similar to those of immature embryonic cardiomyocytes and biochemical and electrophysiological properties similar to those of adult cardiac cells (21) . Such cells, however, cannot be considered completely representative of cardiac myocytes. Thus, our findings must be confirmed using adult cardiac myocytes in culture and, ultimately, in intact hearts. Furthermore, future studies will be required to fully clarify the additional mechanisms responsible for increased glucose use in hypertrophied hearts.
